Navigation Links
Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis
Date:3/31/2011

ipal investigator in the study, commented, "There is a real need for novel therapies in PBC.  The clinically meaningful results from this study are highly supportive of OCA's potential as an effective new drug. We know now that OCA is effective given both in addition to UDCA and, from this study, when given alone.  The reductions in AP levels were very substantial and occurred within a month.  The effects on IgM and inflammatory markers suggest that OCA may have disease modifying properties."

Intercept's Chief Medical Officer, David Shapiro, MD, commented, "This study involved 20 centers in 7 countries and has given us and the PBC thought leaders involved a better understanding of the potent mechanism of action of OCA.  With the international PBC network we have established, we are well positioned to conduct a Phase III program.  We are currently discussing requirements for approval with FDA and have received guidance from the EMA supportive of our proposed program."

Mark Pruzanski, MD, Intercept's Chief Executive Officer, added, "The remarkable results achieved with OCA treatment in this study, together with the previously announced positive Phase II results with our drug added to UDCA in refractory PBC patients and in diabetic patients with nonalcoholic fatty liver disease, supports OCA's potential as a novel hepatoprotective drug that may help preserve liver function in patients with a variety of chronic liver diseases."

About Obeticholic Acid (OCA or INT-747)

OCA is a potent, first-in-class farnesoid X receptor (FXR) agonist derived from the primary human bile acid chenodeoxycholic acid, the natural endogenous FXR agonist. Intercept has announced positive Phase II results from randomized clinical trials in patients with primary biliary cirrhosis (PBC), the most common autoimmune liver disease, and in type 2 diabetics with nonalcoholic fatty liver disease.  These clinical data and OCA's mechanism
'/>"/>

SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease
2. Initiation of FLINT Announced by NIDDK: Study of Intercept Pharmaceuticals Obeticholic Acid (INT-747) in NASH
3. Intercept Pharmaceuticals to Collaborate With NIDDK on Study of Obeticholic Acid (INT-747) in Nonalcoholic Steatohepatitis (NASH)
4. Intercept Pharmaceuticals Raises $25 Million Series B Financing
5. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
6. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
7. Reportlinker Adds Top 500 Pharmaceuticals Industry Report (Global)
8. Reportlinker Adds Top 200 Biopharmaceuticals Industry Report (Global)
9. Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
10. Vanda Pharmaceuticals to Evaluate Tasimelteon in Major Depression
11. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... 2015   DocResponse was ranked the ... a peer-reviewed study , "Evaluation of symptom ... published in the July issue of The British ... Medical School researchers determined that performance of online ... correct diagnosis first in standardized patient evaluations more ...
(Date:7/27/2015)... NAMUR , Belgium , July ... MKT: VNRX), a life sciences company focused on developing ... types and other conditions, today announced that it has ... research organization, Global Specimen Solutions, Inc. (GSS), to support ... colorectal cancer tests. Under the agreement, ...
(Date:7/27/2015)... , July 27, 2015 Research and Markets ... "Intraoperative Imaging Market by Type (Intraoperative CT, Intraoperative ... Asia-Pacific, ROW) - Global Forecast to 2019" report ... expected to reach a value of $2.1 Billion by ... of 3.5% during the forecast period. ...
Breaking Medicine Technology:Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 3VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 2VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 3VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 4VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 5VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 6VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 7Global Intraoperative Imaging (Intraoperative CT, Intraoperative MRI, Intraoperative Ultrasound) Market Forecasts & Trends 2015-2019 2
...  Integware today announced that it has signed a ... PLM Software, a leading global provider of product ... focused for nearly twenty years on extending PLM ... industry. Its platform-neutral development approach enables it to ...
... FLORHAM PARK, N.J., Jan. 25, 2012  Shionogi Inc., the ... announced results from two studies published online today in ... the first study, a randomized, double-blind, placebo-controlled phase III ... 3-16 with problem drooling due to neurologic conditions demonstrated ...
Cached Medicine Technology:Integware Announces Systems Integrator Agreement With Siemens PLM Software 2Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 2Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 3Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 4Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 5Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 6Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 7Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 8
(Date:7/28/2015)... Wilmington, DE (PRWEB) , ... July 28, 2015 , ... ... for 2015. Accounting Today’s annual ranking of Value Added Resellers of ERP Software is ... opportunities they are presented with. This honor represents the second such award in 2015 ...
(Date:7/28/2015)... ... July 28, 2015 , ... Carol McFarland, PT, PhD, ... and demonstration of specific rehabilitation exercises and treatment protocols in the PTA OT ... with an extensive interview conducted by Carol with a board certified neurosurgeon. Specific ...
(Date:7/28/2015)... ... July 28, 2015 , ... Cupertino orthodontist , ... revolutionary orthodontic treatment that allows patients to straighten teeth even without braces. “The ... imaging technology. You wear each set of aligners for about two weeks, removing ...
(Date:7/27/2015)... N.J. (PRWEB) , ... July 28, 2015 , ... Almost ... health plans to offer behavioral health counseling for persons who are obese and those ... happen was less clear. , That mandate will affect any commercial health plan with ...
(Date:7/27/2015)... ... July 27, 2015 , ... Specific cardiovascular risk factors, such ... volumes that may be early indicators of Alzheimer’s disease and dementia, according to ... vascular risk factors damage the brain and can result in cognitive impairment,” said ...
Breaking Medicine News(10 mins):Health News:Intellitec Solutions Named by Accounting Today as Top 100 Value Added Reseller 2Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 2Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 3Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 4Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 5Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 6Health News:Cupertino Invisalign Dentist, Dr. Setareh Mozafari, is Now Offering Complimentary Consultations for Invisalign 2Health News:How Digital Therapeutics Can Help Payers Out of Regulatory Fix 2Health News:How Digital Therapeutics Can Help Payers Out of Regulatory Fix 3Health News:RSNA: Specific Cardiovascular Risk Factors May Predict Alzheimer’s Disease 2Health News:RSNA: Specific Cardiovascular Risk Factors May Predict Alzheimer’s Disease 3
... affect brain function in adults who have few or ... results of the first study to examine cognitive functioning ... funded by the National Heart, Lung, and Blood Institute ... brain function scores and imaging tests in adult patients ...
... lead to future treatments, researchers say , TUESDAY, May ... that are linked to Alzheimer,s disease and could become ... Genetic variants appear to play an important part in ... with the disease increases a person,s risk. It is ...
... out of every ten pregnant women in the United States are ... the May issue of the American Journal of Obstetrics and ... pregnancy, the study shows that higher doses may be needed for ... Denver School of Medicine, lead author of the study said, "We ...
... facts and don,t recognize the symptoms, U.S. survey reveals , TUESDAY, ... women finds only about one in four women aged 25 to ... , This is important because researchers say it takes longer for ... a stroke, and researchers think lack of awareness about symptoms may ...
... ... hierarchically rather than serially, to deliver highly responsive, customer-oriented presentations. , ... London, UK (PRWEB) ... Designer is now available for Microsoft® Office PowerPoint®. This new software enables ...
... 11, 2010 Complex issues in interventional cardiology ... lab will be the focus of the 19th Annual ... DC. The symposium is being held in conjunction with ... of the Cardiovascular Research Foundation. "Changes are occurring ...
Cached Medicine News:Health News:New study suggests sickle cell disease may affect brain function in adults 2Health News:New study suggests sickle cell disease may affect brain function in adults 3Health News:New Alzheimer's Risk Genes Identified 2Health News:New Alzheimer's Risk Genes Identified 3Health News:Many pregnant women not getting enough vitamin D 2Health News:Women Often Miss Signs of Stroke 2Health News:GMARK Launches World's First Web-Like, PowerPoint Navigation Software 2Health News:Nurse/tech symposium at TCT 2010 will address complex issues in the cardiac cath lab 2
... enzymatic cleaner is a fast-acting ... stubborn deposits in as little ... enzymatic cleaner contains an enzyme ... film on soft contact lenses ...
... These specialty Eraser instruments have been ... with the right tool for situations ... a series of 25 gauge intraocular, ... discrete treatment of target tissues for ...
Wet-Field Hemostatic Eraser bipolar tip, packsize is 10/box....
Sterile cordless eraser tips, packsize is 10/box....
Medicine Products: